Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239325 | 0.93 | CYP2C9 (0.59) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL29472028 | 0.93 | CYP2C9 (0.59) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL239326 | 0.93 | CYP2C9 (0.59) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL17591502 | 0.83 | LMNA (0.50) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL14404845 | 0.83 | LMNA (0.50) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL7091919 | 0.80 | CYP2C9 (0.52) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL21728463 | 0.80 | CYP2C9 (0.52) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL12332461 | 0.80 | CYP2C9 (0.52) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL19625972 | 0.78 | LMNA (0.50) | CYP2C9LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL12459466 | 0.76 | CYP2C9 (0.57) | CYP2C9LMNAHPGDMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505878-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9403861-B2 | Salen complexes with dianionic counterions | NOVOMER, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150252145-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-09-10 | — | — | US | disclosed |
| US-8956989-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8951930-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8946109-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140336354-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336354-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NCLN, POLN, NCL | CYP2C9 4344/4885LMNA 938/4885HPGD 3013/4885 |
| US-20150252145-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | CYP2C9 565/4885LMNA 3764/4885HPGD 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.